Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
AstraZeneca reported robust first-quarter 2026 earnings, driven by strong demand for its oncology and rare disease treatments, delivering solid revenue growth and beating analyst expectations. The U.K.-based pharmaceutical giant posted total revenue of $15.29 billion, up from $13.59 billion in the same period last year and above the consensus estimate of $14.94 billion. On a constant currency basis, revenue increased 8% year-over-year, highlighting sustained global demand across its core therapeutic areas.
The company’s oncology portfolio remained a key growth engine, with sales rising 16% year-over-year at constant currency to $6.8 billion. This segment now contributes approximately 44% of AstraZeneca’s total revenue, underscoring its strategic importance. Several flagship cancer drugs delivered notable performance, including Imfinzi, which surged 30% to $1.7 billion, and Enhertu, which jumped 34% to $831 million. Tagrisso, another leading lung cancer therapy, also posted growth, increasing 5% to $1.8 billion.
Core earnings per share (EPS), a key profitability metric that excludes one-off items, came in at $2.58, surpassing analyst forecasts of $2.54 and marking a 5% increase at constant currency. Core operating profit rose 12% to $4.25 billion, reflecting improved operational efficiency and continued investment in commercial capabilities. Meanwhile, net profit climbed to $3.08 billion from $2.92 billion a year earlier.
CEO Pascal Soriot emphasized the company’s strong commercial execution and ongoing investments, noting that AstraZeneca is well-positioned for multiple upcoming product launches and clinical readouts in 2026. The company reiterated its full-year guidance, expecting revenue growth in the mid-to-high single-digit range and core EPS growth in the low double digits.
With continued momentum in its oncology pipeline and expanding rare disease portfolio, AstraZeneca remains a major player in the global pharmaceutical market, attracting investor attention as it works toward its long-term growth ambitions through 2030 and beyond.
